Heterologous vaccine effects

Vaccine

Volumn 34, Issue 34, 2016, Pages 3923-3930

  Saadatian Elahi, Mitra ^a   Aaby, Peter ^b   Shann, Frank ^c   Netea, Mihai G ^d   Levy, Ofer ^e   Louis, Jacques ^f   Picot, Valentina ^f   Greenberg, Michael ^g   Warren, William ^g  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f Fondation Mérieux Applied Research   (France)

^g SANOFI PASTEUR   (France)

Author keywords

Conference report; Heterologous effect; Non antigen specific effects; Off target effects; Vaccine

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; LIVE VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; SMALLPOX VACCINE; VACCINE; INACTIVATED VACCINE;

BCG VACCINATION; CONFERENCE PAPER; DIPHTHERIA; HETEROLOGOUS IMMUNITY; HUMAN; MEASLES; MEASLES VACCINATION; META ANALYSIS (TOPIC); NONHUMAN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALLPOX; SYSTEMATIC REVIEW (TOPIC); TETANUS; TUBERCULOSIS; VACCINATION; FRANCE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INNATE IMMUNITY; ORGANIZATION;

CONGRESSES AS TOPIC; FRANCE; HUMANS; IMMUNITY, HETEROLOGOUS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84979201711     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.020     Document Type: Conference Paper

References (56)

1. [1] Aaby, P., Andersen, M., Sodemann, M., Jakobsen, M., Gomes, J., Fernandes, M., Reduced childhood mortality after standard measles vaccination at 4–8 months compared with 9–11 months of age. BMJ 307:6915 (1993), 1308–1311.
2. [2] Aaby, P., Samb, B., Simondon, F., Seck, A.M., Knudsen, K., Whittle, H., Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 311:7003 (1995), 481–485.
3. [3] Morales, A., Eidinger, D., Bruce, A.W., Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:2 (1976), 180–183.
4. [4] World Health Organization: SAGE meeting of April, Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines. www.who.int/immunization/sage/meetings/2014/april/3_NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf, 2014 [Accessed on 8th February 2016].
5. [5] Mina, M.J., Metcalf, C.J., de Swart, R.L., Osterhaus, A.D., Grenfell, B.T., Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 348:6235 (2015), 694–699, 10.1126/science.aaa3662.
6. [6] Sørup, S., Benn, C.S., Poulsen, A., Krause, T.G., Aaby, P., Ravn, H., Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA 311:8 (2014), 826–835, 10.1001/jama.2014.470.
7. [7] Aaby, P., Martins, C.L., Garly, M.L., Andersen, A., Fisker, A.B., Claesson, M.H., et al. Measles vaccination in the presence or absence of maternal measles antibody: impact on child survival. Clin Infect Dis 59:4 (2014), 484–492, 10.1093/cid/ciu354.
8. [8] Bottomley, C., Bojang, A., Smith, P.G., Darboe, O., Antonio, M., Foster-Nyarko, E., et al. The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study. Emerg Themes Epidemiol, 12(1), 2015, 1, 10.1186/s12982-014-0022-3 eCollection 2015.
9. [9] Aaby, P., Benn, C.S., Nielsen, J., Lisse, I.M., Rodrigues, A., Ravn, H., Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. BMJ Open, 2, 2012, e000707.
10. [10] Aaby, P., Hedegaard, K., Sodemann, M., Nhante, E., Veirum, J.E., Jakobsen, M., et al. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau. Vaccine 23:14 (2005), 1746–1751.
11. [11] Lund, N., Andersen, A., Hansen, A.S., Jepsen, F.S., Barbosa, A.G., Biering-Sørensen, S., et al. The effect of oral polio vaccine at birth on mortality. A randomized trial. Clin Infect Dis 61:10 (2015), 1504–1511, 10.1093/cid/civ617.
12. [12] Mayr, A., Taking advantage of the positive side-effects of smallpox vaccination. J Vet Med B Infect Dis Vet Public Health 51:5 (2004), 199–201.
13. [13] Mercer, A.J., Smallpox and epidemiological-demographic change in Europe: the role of vaccination. Popul Stud (Camb) 39:2 (1985), 287–307.
14. [14] Jensen, M.L., Dave, S., Schim van der Loeff, M., da Costa, C., Vincent, T., Leligdowicz, A., et al. Vaccinia scars associated with improved survival among adults in rural Guinea-Bissau. PLoS ONE, 1, 2006, e101.
15. [15] Aaby, P., Gustafson, P., Roth, A., Rodrigues, A., Fernandes, M., Sodemann, M., et al. Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. Vaccine 24:29–30 (2006), 5718–5725.
16. [16] Sørup, S., Villumsen, M., Ravn, H., Benn, C.S., Sørensen, T.I., Aaby, P., et al. Smallpox vaccination and all-cause infectious disease hospitalization: a Danish register-based cohort study. Int J Epidemiol 40:4 (2011), 955–963, 10.1093/ije/dyr063.
17. [17] Krone, B., Kölmel, K.F., Henz, B.M., Grange, J.M., Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 41:1 (2005), 104–117.
18. [18] Kölmel, K.F., Grange, J.M., Krone, B., Mastrangelo, G., Rossi, C.R., Henz, B.M., et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 41:1 (2005), 118–125.
19. [19] Vaccinia (Smallpox) Vaccine. Recommendations of the Advisory Committee for Immunization Program (ACIP 2001) MMWR 2001. Vol 50; No.RR-10 < http://www.cdc.gov/mmwr/pdf/rr/rr5010.pdf> [Accessed on December 14th 2015].
20. [20] Kern, A.B., Schiff, B.L., Smallpox vaccination in the management of recurrent herpes simplex: a controlled evaluation. J Invest Dermatol 33 (1959), 99–102.
21. [21] Biering-Sørensen, S., Aaby, P., Napirna, B.M., Roth, A., Ravn, H., Rodrigues, A., et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J 31:3 (2012), 306–308, 10.1097/INF.0b013e3182458289.
22. [22] Aaby, P., Roth, A., Ravn, H., Napirna, B.M., Rodrigues, A., Lisse, I.M., et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?. J Infect Dis 204:2 (2011), 245–252, 10.1093/infdis/jir240.
23. [23] Nankabirwa, V., Tumwine, J.K., Mugaba, P.M., Tylleskär, T., Sommerfelt, H., PROMISE-EBF Study Group. Child survival and BCG vaccination: a community based prospective cohort study in Uganda. BMC Public Health, 15, 2015, 175, 10.1186/s12889-015-1497-8015-1497-8.
24. [24] Kristensen, I., Aaby, P., Jensen, H., Routine vaccinations and child survival: follow up study in Guinea-Bissau. West Africa BMJ 321:7274 (2000), 1435–1438.
25. [25] Shann, F., Editorial commentary: different strains of Bacillus Calmette-Guérin vaccine have very different effects on tuberculosis and on unrelated infections. Clin Infect Dis 61:6 (2015), 960–962, 10.1093/cid/civ454.
26. [26] Favorov, M., Ali, M., Tursunbayeva, A., Aitmagambetova, I., Kilgore, P., Ismailov, S., et al. Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan. PLoS ONE, 7(3), 2012, e32567, 10.1371/journal.pone.0032567.
27. [27] Pearl, R., Cancer and tuberculosis. Am J Hygiene, 9, 1929, 97.
28. [28] Old, L.J., Clarke, D.A., Benacerraf, B., Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 184:Suppl 5 (1959), 291–292.
29. [29] Zbar, B., Bernstein, I.D., Rapp, H.J., Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst 46:4 (1971), 831–839.
30. [30] Mathé, G., Amiel, J.L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J.R., et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1:7597 (1969), 697–699.
31. [31] Morton, D.L., Eilber, F.R., Holmes, E.C., Hunt, J.S., Ketcham, A.S., Silverstein, M.J., et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180:4 (1974), 635–643.
32. [32] Redelman-Sidi, G., Glickman, M.S., Bochner, B.H., The mechanism of action of BCG therapy for bladder cancer – a current perspective. Nat Rev Urol 11:3 (2014), 153–162, 10.1038/nrurol.2014.15.
33. [33] Aaby, P., Martins, C.L., Garly, M.L., Bale, C., Andersen, A., Rodrigues, A., et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ, 341, 2010, c6495.
34. [34] Sun, J.C., Ugolini, S., Vivier, E., Immunological memory within the innate immune system. EMBO J c33:12 (2014), 1295–1303, 10.1002/embj.20138765.
35. [35] Ritz, N., Mui, M., Balloch, A., Curtis, N., Non-specific effect of Bacille Calmette-Guérin vaccine on the immune response to routine immunisations. Vaccine 31:30 (2013), 3098–3103, 10.1016/j.vaccine.2013.03.059.
36. [36] Netea, M.G., Quintin, J., van der Meer, J.W., Trained immunity: a memory for innate host defense. Cell Host Microbe 9:5 (2011), 355–361, 10.1016/j.chom.2011.04.006.
37. [37] Quintin, J., Saeed, S., Martens, J.H., Giamarellos-Bourboulis, E.J., Ifrim, D.C., Logie, C., et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12:2 (2012), 223–232, 10.1016/j.chom.2012.06.006.
38. [38] Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L.A., Ifrim, D.C., Saeed, S., et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 109:43 (2012), 17537–17542, 10.1073/pnas.1202870109.
39. [39] Wynn, J.L., Scumpia, P.O., Winfield, R.D., Delano, M.J., Kelly-Scumpia, K., Barker, T., et al. Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood 112:5 (2008), 1750–1758, 10.1182/blood-2008-01-130500.
40. [40] Levy, O., Netea, M.G., Innate immune memory: implications for development of pediatric immunomodulatory agents and adjuvanted vaccines. Pediatr Res 75:1–2 (2014), 184–188, 10.1038/pr.2013.214.
41. [41] Buffen, K., Oosting, M., Quintin, J., Ng, A., Kleinnijenhuis, J., Kumar, V., et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog, 10(10), 2014, e1004485, 10.1371/journal.ppat.1004485 eCollection 2014 Oct.
42. [42] Yáñez, A., Hassanzadeh-Kiabi, N., Ng, M.Y., Megías, J., Subramanian, A., Liu, G.Y., et al. Detection of a TLR2 agonist by hematopoietic stem and progenitor cells impacts the function of the macrophages they produce. Eur J Immunol 43:8 (2013), 2114–2125, 10.1002/eji.201343403.
43. [43] Nagai, Y., Garrett, K.P., Ohta, S., Bahrun, U., Kouro, T., Akira, S., et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 24:6 (2006), 801–812.
44. [44] De Groot, A.S., Ardito, M., McClaine, E.M., Moise, L., Martin, W.D., Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008–2009 conventional influenza vaccine. Vaccine 27:42 (2009), 5740–5747, 10.1016/j.vaccine.2009.07.040.
45. [45] Moise, L., Terry, F., Gutierrez, A.H., Tassone, R., Losikoff, P., Gregory, S.H., et al. Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection. Front Microbiol, 5, 2014, 502, 10.3389/fmicb.2014.00502 eCollection 2014.
46. [46] Aaby, P., Garly, M.L., Nielsen, J., Ravn, H., Martins, C., Balé, C., et al. Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanus-pertussis vaccines: observations from vaccination trials in Guinea-Bissau. Pediatr Infect Dis J 26:3 (2007), 247–252.
47. [47] Klein, S.L., Shann, F., Moss, W.J., Benn, C.S., Aaby, P., RTS, S malaria vaccine and increased mortality in girls. mBio 7:2 (2016), e00514–e00516, 10.1128/mBio.00514-16 pii: e00514-16.
48. [48] Aaby, P., Kollmann, T.R., Benn, C.S., Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol 15:10 (2014), 895–899, 10.1038/ni.2961.
49. [49] Fisker, A.B., Rodrigues, A., Martins, C., Ravn, H., Byberg, S., Thysen, S., et al. Reduced all-cause child mortality after general measles vaccination campaign in rural Guinea-Bissau. Pediatr Infect Dis J, 2015 [Epub ahead of print].
50. [50] Tribouley, J., Tribouley-Duret, J., Appriou, M., Effect of Bacillus Callmette Guerin (BCG) on the receptivity of nude mice to Schistosoma mansoni. C R Seances Soc Biol Fil 172:5 (1978), 902–904.
51. [51] van ’t Wout, J.W., Poell, R., van Furth, R., The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol 36:5 (1992), 713–719.
52. [52] Bistoni, F., Vecchiarelli, A., Cenci, E., Puccetti, P., Marconi, P., Cassone, A., Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 51:2 (1986), 668–674.
53. [53] Bistoni, F., Verducci, G., Perito, S., Vecchiarelli, A., Puccetti, P., Marconi, P., et al. Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection. J Med Vet Mycol 26:5 (1988), 285–299.
54. [54] Levy, O., Levy, O., Ready to benefit from training: heterologous effects of early life immunization. Trans R Soc Trop Med Hyg 109:1 (2015), 3–4, 10.1093/trstmh/tru185.
55. [55] Sanchez-Schmitz, G., Levy, O., Development of newborn and infant vaccines. Sci Transl Med, 3(90), 2011, 90ps27, 10.1126/scitranslmed.3001880.
56. [56] Dowling, D.J., Levy, O., Ontogeny of early life immunity. Trends Immunol 35:7 (2014), 299–310, 10.1016/j.it.2014.04.007.